B-TYPE NATRIURETIC PEPTIDE

Code
400.4488
Name
B-TYPE NATRIURETIC PEPTIDE
Category
None
Department
Chemistry
Start Date
Expiration Date
Synonyms
BNP; Brain Type Natriuretic Polypeptide
CPT Codes
83880
Site
Main Lab
Reference Test
ATLAS Test Code

B NAT PEP

Specimen Information

Type

Lavender, EDTA

Volume

2.0 ml

Transport Info

Whole Blood 3 days Room Temperature, 6 days Refrigerated

Fasting Required?
False
Patient Instructions

Reference Range

Age <50 years: 0-450pg/mL

Age 50-75 years: 0-900pg/mL

Age >75 years: 0-1800pg/mL

Methodology

Chemiluminescence

Clinical Significance

Of use in the diagnosis of early-stage congestive heart failure (CHF). In response to a rise in blood pressure, the heart releases two peptides. Of the two, brain-type natriuretic peptide (BNP) is the cardiac hormone that is released from the ventricles. It derives its name from the fact that it was first discovered in brain tissue. BNP lowers blood pressure by: 1) relaxing arterioles, 2) inhibiting the secretion of renin and aldosterone, and 3) inhibiting the reabsorption of sodium ions by the kidneys. The latter two effects reduce the reabsorption of water by the kidneys. The volume of urine increases, as does the amount of sodium excreted in it. These effects give BNP its name (natrium = sodium; uresis = urinate). The net effect of these actions is to reduce blood pressure by reducing the volume of blood in the circulatory system. BNP is part of a system regulating blood pressure and fluid balance. It is continuously released from the heart in response to both ventricular volume expansion and pressure overload. Diagnosing congestive heart failure (CHF) in very early stages permits early interventions that might prevent the disease from advancing.Various studies have demonstrated that circulating BNP concentrations increase with the severity of CHF based on the NYHA classification. There is a positive correlation between blood BNP concentrations and left ventricular end diastolic pressure and inverse correlation to left ventricular function. Thus, BNP provides an independent assessment of left ventricular function without the use of other invasive or expensive diagnostic tests.BNP concentration in control Non-CHF population increases with age, with a mean of 13.9 at age 45 and 63.7 at age 75. Females have higher concentrations than males. The percentage of patients in each NYHA functional class having levels greater than 100 pg/mL.

Back

Patients & Visitors

Make a First Appointment Maternity Pre-Registration Make a Donation Recognize a Sarah Bush Lincoln Employee